THE ABBVIE SCANDINAVIA GOLDEN TICKET
The AbbVie Scandinavia Golden Ticket programme provides one year’s access to:
- Lab space, financed by AbbVie, with access to research and office facilities and services, provided by SmiLe on site in Lund
- Mentoring and business coaching from SmiLe throughout the year
- Tailored support from AbbVie’s international researchers and mentors
- Exclusive access to AbbVie and SmiLe networks throughout the year with the possibility of future collaboration
The AbbVie Scandinavia Golden Ticket will be awarded to one early-stage company developing novel, transformational therapies for immunology, oncology, neuroscience, eye care or aesthetics.
WHO CAN APPLY?
The ideal candidate for winning an AbbVie Scandinavia Golden Ticket will meet the following criteria:
- Focused on science / technology with potential to generate transformational therapies in areas that align strategically with AbbVie’s therapeutic areas of interest (listed above and additional details available here)
- Developing therapeutic platform technologies, including gene therapy, novel cell therapy, gene editing, or novel drug-discovery or platform technologies, including AI- platforms for drug discovery (for additional criteria, see here)
APPLICATIONS ARE NOW CLOSED
To apply, please upload your non-confidential company presentation (10 slide limit) by January 19th, 2024.
For detailed application instructions, see here
Selected applicants will be invited to present their company to an expert AbbVie leadership panel at an event to be held in-person at SmiLe Incubator in February, 2024. We look forward to receiving your application.
AAX Biotech’s Growth Story: Insights from Abbvie’s 2024 Golden Ticket Winner
ANY QUESTIONS?
Thomas Areschoug
Business Coach
thomas.areschoug@smileventurehub.com
Frequently Asked Questions
Who is eligible to apply?
To apply for AbbVie Scandinavia Golden Ticket companies must fulfill the below criteria:
- Focused on science / technology with potential to generate transformational therapies in areas that align strategically with AbbVie’s therapeutic areas of interest (listed above and additional details available here)
- Developing therapeutic platform technologies, including gene therapy, novel cell therapy, gene editing, or novel drug-discovery or platform technologies, including AI- platforms for drug discovery. (Please note that Diagnostics, Devices, Research Tools, and Healthcare Services/IT are excluded.)
- The company must not have a major partnership with another large biopharmaceutical company; however, current, or prior recipients of similar awards sponsored by other companies or lab spaces are eligible to apply.
- Total equity funding raised must be less than 7M Euros before application.
- The company must not have sales revenue.
- The company must be in the life sciences and have an impact on human health.
- The company awarded the AbbVie Scandinavia Golden ticket must be financially and scientifically ready to move into Smile Incubator within two-nine months after receiving the Golden Ticket. Companies that do not have their principal place of business in Sweden must be willing to relocate/open subsidiary in Sweden.
How to apply?
Please create a non-confidential presentation of no more than ten slides that emphasize:
- Company’s mission
- Management team & expertise
- The science behind the technology or asset
- The prioritized and potentially applicable indications
- Differentiation point: What makes your technology different from the competitors?
- Relevant IP and publications that include data supporting your science
- Mitigation of Risk: What are the potential pitfalls and key challenges
- Roadmap and growth plan for the timeframe of the Golden Ticket award
Fill in the form and upload your presentation in English or Swedish.
Applicant may only submit one entry. Please send your application by January 19, 2024.